Microsoft Hong Kong and HKSTP join forces to introduce "TechConnect" co-incubation programme to empower global startups growing in Hong Kong
A collaboration to empower startups' ambition, turning vision into momentums
HONG KONG SAR - Media OutReach Newswire - 20 May 2025 - Microsoft Hong Kong and the Hong Kong Science and Technology Parks Corporation (HKSTP) announced the launch of "TechConnect", a 12-month co-incubation programme designed to empower local and global startups seeking to establish and scale their presence in the Hong Kong market. As part of Microsoft Hong Kong's annual project "HKonnect+", this collaborative initiative will mainly focus on driving innovation in smart city solutions, particularly within the burgeoning sectors of property technology, marketing technology, and retail solutions. By leveraging the strength and resources of Microsoft Hong Kong and HKSTP, the collaboration aims to provide comprehensive, end-to-end support to promising startups, facilitating their successful entry and growth within Hong Kong's thriving tech ecosystem.
The collaboration was introduced in an opening ceremony by representatives from Microsoft Hong Kong and HKSTP, which underscores a shared commitment to fostering innovation and supporting the development of cutting-edge technologies in Hong Kong.
Application to the "TechConnect" programme is now opened. Local and overseas startups are encouraged to apply via https://bit.ly/43m2eAz.
Unparalleled benefits for participating startups to pave way for success
The "TechConnect" programme offers a suite of unparalleled benefits designed to accelerate the growth and success of participating startups, which will be supported by the unique resources of Microsoft Hong Kong and HKSTP.
Benefits that are going to be provided by Microsoft Hong Kong shed light on financial and technical support and business matching opportunities, including over HKD$1,100,000 in Microsoft Azure credits, granting startups free access to a wide range of Microsoft tools and exclusive offers, including GitHub Enterprise, Azure OpenAI Service, and VS Code, enabling them to leverage powerful technology for building and scaling their solutions. Participants will also benefit from comprehensive training workshops conducted by industry experts, covering key areas such as business strategy, technology development, and market entry. Ultimately, the programme will culminate in an exclusive DEMO Day, where startups will have the opportunity to pitch their solutions to leading investors, industry partners, and potential clients, fostering valuable business matching opportunities.
Meanwhile, HKSTP will offer up to HKD$100,000 through its Ideation Programme, providing crucial financial assistance during the early development stage of the tech companies. Startups will also gain access to co-working space, fostering a collaborative and productive environment. Eligible startups will also have the opportunity to apply for additional funding via HKSTP's Incubation Programme, further fuelling their growth and expansion.
In addition, both parties will also jointly provide expert training, coaching, and unlimited learning resources on technology enablement and business growth. Exclusive startups offers, such as perks from LinkedIn, Stripe Atlas, Bubble, and other trusted partners, will also be included.
Henry Li, Head of Global Partner Solutions at Microsoft Hong Kong shared, "We are pleased to launch this groundbreaking co-incubation programme with HKSTP, which further strengthens Microsoft Hong Kong's "HKonnect+" vision. By combining our cutting-edge technology resources and global industry expertise with HKSTP's invaluable local market insights and established network, we are creating a powerful, synergistic ecosystem for innovation and accelerated growth, which will significantly reduce the hurdles startups face when they wish to establish presence in the Hong Kong market. We are eager to witness the tangible and positive impact these startups will have on Hong Kong's future, driving technological advancement and improving the lives of our citizens."
Derek Chim, Head of Startup Ecosystem and Development at HKSTP added, "We are thrilled to partner with Microsoft Hong Kong to launch the co-incubation programme. By providing essential support from funding, infrastructure to strategic support tailored to the unique challenges startups commonly encounter, we are empowering local and global innovators to scale up by bringing their transformative solutions to our city. We are looking forward to receiving exciting proposals that will create positive impact to Hong Kong's innovation and technology landscape."
Hashtag: #MicrosoftHongKong
The issuer is solely responsible for the content of this announcement.
About Microsoft
Microsoft (Nasdaq "MSFT" @microsoft) creates platforms and tools powered by AI to deliver innovative solutions that meet the evolving needs of our customers. The technology company is committed to making AI available broadly and doing so responsibly, with a mission to empower every person and every organization on the planet to achieve more.
About Hong Kong Science and Technology Parks Corporation
Hong Kong Science and Technology Parks Corporation (HKSTP) is Hong Kong's largest innovation and technology incubator, serving a vibrant community of over 24,000 professionals. With more than 2,200 tech startups from over 26 countries / regions, HKSTP offers end-to-end incubation support—from ideation to scale-up—alongside world-class R&D facilities and infrastructure. As a leading driver of innovation, HKSTP propels to thrive and grow in Hong Kong and beyond.
Microsoft
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
3 days ago
- Zawya
Henderson Land Sets Record for Central's Largest Single Office Lease
New Central Harbourfront Site 3 Project Leases Over 70% of Phase 1 Office Premises HONG KONG SAR - Media OutReach Newswire - 18 June 2025 - Henderson Land Development Company Limited ("Henderson Land" or "The Group") (Stock code 12) is delighted to announce that, through its subsidiary, it has entered into an Agreement for Lease with Jane Street, a quantitative trading firm and liquidity provider, as the first anchor tenant of the Group's latest New Central Harbourfront flagship development project. Jane Street will occupy over 223,000 square feet across six floors, leasing over 70% of the development's Phase 1 premium office and ancillary space. The signing of the lease is nearly two years ahead of the anticipated handover in early 2027. This lease marks the largest single office leasing transaction for Hong Kong's Central Business District in decades. Chairman of Henderson Land, Dr. Martin Lee Ka-shing, said: "We are proud to welcome Jane Street to our New Central Harbourfront flagship development project." He added, "Deeply rooted in Hong Kong, our Group is committed to advancing the city's core districts, and this anchor tenancy reinforces Hong Kong's unrivalled position as an international financial powerhouse. This development will reinvent Central by connecting the multi-worlds of retail, culture and commerce with nature and entertainment. Fuelled by the passion of our talented teams, we are confident that this global development will connect Hong Kong to the world stage, forging a bold new chapter for the city's future." The New Central Harbourfront project spans over 1.6 million square feet of gross floor area. This transformative project will not only redefine the city's iconic skyline, but also elevate Central as a cutting edge, vibrant global district. The 400 meter-long development includes 700,000 square feet of office and ancillary space that offers the largest premium Grade-A Office floor plates in Central, 900,000 square feet of retail space and the first Broadway-calibre theatre in Central. Inspired by a concept of "The Bridge", this people-centric development is a superconnector that seamlessly bridges Hong Kong and the world, enhances connectivity in Central and fosters integration with its surroundings – strengthening synergies between urban and nature, commerce and culture. The development provides an unprecedented 300,000 square feet of green and open spaces, including a rooftop garden for public enjoyment. It links Central district's vibrancy to the waterfront and the iconic Victoria Harbour, forming the new heart of Central. The site will unfold in two phases, with Phase 1 set for completion in the fourth quarter of 2026, and Phase 2 in 2032. Two years ahead of its first phase opening, the project has earned the highest standard industry certifications for its sustainability-focused architectural design, including awards and accreditations from LEED, BEAM Plus, WiredScore, Construction Industrial Council (CIC), Green Business Certification Inc., The Hong Kong Institute of Surveyors and Hong Kong Green Building Council. Hashtag: #HendersonLand The issuer is solely responsible for the content of this announcement. About Henderson Land Group Founded in 1976 and listed in Hong Kong since 1981, Henderson Land Development Company Limited (Stock code: 12) is a leading property group, focusing on Hong Kong and mainland China. Henderson Land is carrying on its legacy into the future, curating a property portfolio that grows from strength to strength and encompasses award-winning landmark projects such as the International Finance Centre complex and The Henderson. In addition to its core business in property development and property investment, the Group holds strategic investments in two listed subsidiaries (namely, Miramar Hotel and Investment Company Limited and Henderson Investment Limited) and three listed associates (namely, The Hong Kong and China Gas Company Limited (which in turn has equity stakes in a listed subsidiary, Towngas Smart Energy Company Limited), Hong Kong Ferry (Holdings) Company Limited and Sunlight Real Estate Investment Trust). Henderson Land is dedicated to the long-term commitment of sustainability and is a pioneer in green building and sustainable practices, which harness innovation and technology to create new, smarter living. The Group is also a strong advocate of social responsibility and invests in a broad range of community causes and initiatives. For more information, please visit About Jane Street Jane Street is a global quantitative trading firm and liquidity provider with expertise in a wide range of financial products, including ETFs, equities, futures, commodities, options, bonds, and currencies. Founded in 2000, Jane Street has offices in New York, London, Hong Kong, Amsterdam, and Singapore. Jane Street's global footprint allows it to make markets continually on more than 200 electronic exchanges and other trading venues in more than 45 countries around the world. Henderson Land Development Company Limited
Arabian Post
3 days ago
- Arabian Post
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth HONG KONG SAR – Media OutReach Newswire – 17 June 2025 – Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) – to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. In collaboration with InvestHK, HKSTP joined forces with the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) for the first time to form a delegation and led 16 prominent life and health technology companies to showcase at BIO 2025 held in Boston, USA. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. ADVERTISEMENT During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. , partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: 'We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation.' Ahead of BIO 2025, the delegation participated in the '2025 Biomedical Pitch Competition', co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as 'Edison of Medicine'), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: ADVERTISEMENT Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at
Zawya
4 days ago
- Zawya
HKSTP Teams Up with HKU and CUHK Medical Schools to Showcase Hong Kong's Life & Health Innovations at BIO International Convention
Seizing Global Business and Investment Opportunities for Sustainable Growth HONG KONG SAR - Media OutReach Newswire - 17 June 2025 - Hong Kong Science and Technology Parks Corporation (HKSTP), in collaboration with InvestHK, led 16 prominent life and health technology companies to BIO 2025, the world's largest biotechnology event, held in Boston, USA, from June 16 to 19. This year marks the first time HKSTP joined forces with Hong Kong's two leading medical faculties—the LKS Faculty of Medicine at The University of Hong Kong (HKU) and the Faculty of Medicine at The Chinese University of Hong Kong (CUHK) - to form a delegation, showcasing Hong Kong's cutting-edge research capabilities and innovation potential in life sciences and health technologies. The initiative further strengthens Hong Kong's position as a world-class biotech innovation hub. The HKSTP Pavilion highlighted the groundbreaking technologies and products of its park companies, featuring innovative solutions across diverse fields such as novel drug development, diagnostic technologies, and medical innovation. Among the 16 participating companies, they were the members of HKSTP's incubation programmes including Incu-Bio and ELITE Programme, cutting-edge work from the InnoHK research centers, and other outstanding biotech companies. On the first day of the exhibition, the delegation successfully attracted attention from global industry leaders, corporate partners, and venture capital firms. During BIO 2025, HKSTP and its park companies made significant strides in fostering cross-border innovation ecosystems and exploring new market opportunities: Immuno Cure, partnering with HKUMed, the developer of the first-in-human novel therapeutic HIV vaccine ICVAX, announced its collaboration with PharmaJet to explore the application of a needle-free vaccination solution, accelerating the global commercialization pathway for ICVAX. HKSTP signed a partnership agreement with DLRC to provide legal advisory services in clinical trials and certification, promoting global ecosystem collaboration and growth. Mr. Albert Wong, CEO of HKSTP, said: "We are thrilled to partner with two leading medical schools for the first time at BIO 2025, demonstrating Hong Kong's breakthroughs and innovation in life and health technology. This delegation not only deepens collaboration between Hong Kong and top global research institutions but also highlights our unique advantages as a core I&T hub in the Greater Bay Area. With strong policy and funding support from the HKSAR government, Hong Kong will further serve as a bridge connecting Mainland China and global tech partnerships, solidifying its leadership in life sciences innovation." Ahead of BIO 2025, the delegation participated in the "2025 Biomedical Pitch Competition", co-organized by the Boston Capital Investment Club (BCIC) and HKSTP. The event connects global life and health innovators with investors and business partners. Three HKSTP companies—ARBELE, GenEditBio, and Cogsmart—excelled in the preliminary rounds, competing against over 100 global life sciences firms, with ARBELE, HKUMed's affiliated spin-off company, winning the championship, underscoring Hong Kong's research excellence. Over the past three years, this platform has helped startups secure over USD 100 million in funding and connect with hundreds of international investors and partners, driving further business growth. HKSTP is committed to propelling Hong Kong's life sciences sector onto the global stage, showcasing the city's unique strengths to attract international enterprises and talent. The delegation also organized networking events and visits, enabling Hong Kong companies to engage with overseas investors, leading corporations, and renowned academic institutions, including visits to MIT Professor Robert Langer (Described as "Edison of Medicine"), Harvard Innovation Labs, Cambridge Innovation Center, and more. This initiative reinforces Hong Kong's sustainable development in life sciences and its role as a global innovation leader. Appendix: List of Park Companies Participating in BIO 2025: Allegrow Biotech Limited ARBELE Limited Beth Bioinformatics Co., Limited Centre for Translational Stem Cell Biology The Centre for Virology, Vaccinology, and Therapeutics DECODE CURE Limited GenEditBio Limited Great Bay Bio Hong Kong Universal Biologicals Company Limited Immuno Cure Holding (HK) Limited The Institute for Innovation, Translation and Policy Research (ITPR) LEE'S PHARMACEUTICAL (HK) LIMITED Serilink Biotechnology Company Limited Xiaomo Biotech Limited XUXIN (HongKong) Biotechnology Co., Limited Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Limited Hashtag: #HKSTP The issuer is solely responsible for the content of this announcement. About Hong Kong Science and Technology Parks Corporation Hong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 13 unicorns, more than 15,000 research professionals and over 2,300 technology companies from 25 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc. Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined. Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more. Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in stablishing I&T as a pillar of growth for Hong Kong. More information about HKSTP is available at Hong Kong Science and Technology Parks Corporation
